星空传媒

Skip to main content

Alzheimer's drug that can slow disease gets backing from FDA advisers

A sign for Eli Lilly and Co. sits outside their corporate headquarters in Indianapolis on April 26, 2017. (Darron Cummings/AP file photo) A sign for Eli Lilly and Co. sits outside their corporate headquarters in Indianapolis on April 26, 2017. (Darron Cummings/AP file photo)
Share

A closely watched Alzheimer's drug from Eli Lilly won the backing of federal health advisers on Monday, setting the stage for the treatment's expected approval for people with mild dementia caused by the brain-robbing disease.

Food and Drug Administration (FDA) advisers voted unanimously that the drug's ability to modestly slow the disease outweighs its risks, including side effects like brain swelling and bleeding that will have to be monitored.

鈥淚 thought the evidence was very strong in the trial showing the effectiveness of the drug,鈥 said panel member Dean Follmann, a National Institutes of Health statistician.

The FDA will make the final decision on approval later this year. If the agency agrees with the panel's recommendation, the drug, donanemab, would only be the second Alzheimer鈥檚 drug cleared in the U.S. shown to convincingly slow cognitive decline and memory problems due to Alzheimer's. The FDA approved a similar infused drug, Leqembi, from Japanese drugmaker Eisai last year.

Lilly studied its drug by grouping patients based on their levels of a brain protein, called tau, that predicts severity of cognitive problems. That prompted FDA reviewers to question whether patients might need to be screened via brain scans for tau before getting the drug. But most panelists thought there was enough evidence of the drug's benefit to prescribe it broadly, without screening for the protein.

鈥淚mposing a requirement for tau imaging is not necessary and would raise serious practical and access concerns to the treatment,鈥 said Dr. Thomas Montine of Stanford University, who chaired the panel and summarized its opinion.

The FDA had been widely expected to approve the drug in March. But instead the agency said it would ask its panel of neurology experts to publicly review the company鈥檚 data, an unexpected delay that surprised analysts and investors.

Researchers are trying to see if lifestyle interventions show cognitive improvement in people with mild cognitive impairment or early dementia due to Alzheimer鈥檚 disease. (Matt Rourke/AP Photo)

At a high level, Lilly鈥檚 results mirrored those of Leqembi, with both medications showing a modest slowing of cognitive problems in patients with early-stage Alzheimer鈥檚. The Indianapolis-based company conducted a 1,700-patient study showing patients who received monthly IV infusions of its drug declined about 35 per cent more slowly than those who got a sham treatment.

But there were differences in the way Lilly tested its drug that raised questions for FDA.

One change was measuring patients' tau, and excluding patients with very low or no levels of the protein. But panelists said there was enough data from other measures to feel confident that nearly all patients could benefit from the drug, regardless of their levels.

In another key difference, Lilly studied taking patients off its drug when they reached very low levels of amyloid, a sticky brain plaque that's a contributor to Alzheimer's.

Lilly scientists suggested stopping treatment is a key advantage for its drug, which could reduce side effects and costs. But FDA staff said Lilly provided little data supporting the optimal time to stop or how quickly patients might need to restart treatment.

Despite those questions, many panelists thought the possibility of stopping doses held promise.

鈥淚t鈥檚 a huge cost savings for the society, we鈥檙e talking about expensive treatment, expensive surveillance,鈥 said Dr. Tanya Simuni of Northwestern University. She and others experts said patients would need to be tracked and tested to see how they fare and if they need to resume treatment.

The main safety issue with donanemab was brain swelling and bleeding, a problem common to all amyloid-targeting drugs.

Three deaths in the donanemab study were linked to the drug, according to the FDA, all involving brain swelling or bleeding. One of the deaths was caused by a stroke, a life-threatening complication that occurs more frequently among Alzheimer's patients.

FDA's panel agreed that those the risks could be addressed by warning labels and education for doctors as well as medical scans to identify patients at greater risk of stroke.

CTVNews.ca 星空传媒

A driver suffered only minor injuries after going airborne in a residential neighbourhood in Maple Ridge, B.C., on Friday, the car eventually landing on its roof in someone鈥檚 backyard.

The owners of a North York condominium say they are facing a $70,000 special assessment to fix their building's parking garage. '$70,000 is a lot of money. It makes me very nervous and stressed out of nowhere for this huge debt to come in,' said Ligeng Guo.

Police released the identities of the mother and daughter who were killed after a fire tore through a 160-year-old building in Old Montreal on Friday.

The sentencing of the man who pleaded guilty in the deadly hit-and-run in Kitsilano two years ago began on Friday.

Local Spotlight

Chantal Kreviazuk is set to return to Winnipeg to mark a major milestone in her illustrious musical career.

From the beaches of Cannes to the bustling streets of New York City, a new film by a trio of Manitoba directors has toured the international film festival circuit to much pomp and circumstance.

A husband and wife have been on the road trip of a lifetime and have decided to stop in Saskatchewan for the winter.

The grave of a previously unknown Canadian soldier has been identified as a man from Hayfield, Man. who fought in the First World War.

A group of classic car enthusiasts donated hundreds of blankets to nursing homes in Nova Scotia.

Moving into the second week of October, the eastern half of Canada can expect some brisker fall air to break down from the north

What does New Westminster's t蓹m蓹sew虛tx史 Aquatic and Community Centre have in common with a historic 68,000-seat stadium in Beijing, an NFL stadium and the aquatics venue for the Paris Olympics? They've all been named among the world's most beautiful sports venues for 2024.

The last living member of the legendary Vancouver Asahi baseball team, Kaye Kaminishi, died on Saturday, Sept. 28, surrounded by family. He was 102 years old.

New data from Greater Vancouver and the Fraser Valley shows a surge in supply and drop in demand in the region's historically hot real estate market.